Key result
Single defibrillator testing during ICD implantation showed no significant differences in neuronal damage or cognitive impairment compared to untested patients.
Why the study?
Studies have shown increases in neuronal damage markers after defibrillator threshold testing with multiple shocks, prompting evaluation of the effects of a single DFT.
Does single defibrillator testing (DFT) cause neuronal damage or cognitive impairment in patients undergoing transvenous ICD implantation?
Observational (n=23)
Does single defibrillator testing (DFT) cause neuronal damage or cognitive impairment in patients undergoing transvenous ICD implantation?
Single defibrillator testing during ICD implantation does not lead to signs of neuronal damage or cognitive impairment in selected patients without pre-existing cerebral vasculopathy.
Answers are grounded in this paper and cite their sources.
Single DFT was not associated with added neuronal or cognitive risk; leaves open whether routine testing can be safely omitted.
Background Defibrillator testing (DFT) is still used in selected patients to ensure adequate therapy. To do so, ventricular fibrillation is induced and terminated by the implanted cardioverter defibrillator (ICD). Studies have shown increases in neuronal damage markers without a measurable clinical effect in patients after defibrillator threshold testing with multiple shocks. Objective The aim of this study was to measure clinical outcomes, neuronal damage parameters (NSE and S100), and intraoperative cerebral perfusion (Doppler, near infra‐red spectroscopy [NIRS]) in patients undergoing single DFT after transvenous ICD implantation and comparing them to untested patients. Method We included 23 patients. Nine underwent surgery with a single DFT, 14 were not tested. Cognitive impairment was tested using the Mini‐Mental‐Status Test (MMST) and the DEMTECt 24 h prior and postsurgery. We also measured S100 and Neuron‐Specific Enolase (NSE) at these timepoints. During surgery we measured medial cerebral artery velocity and cerebral tissue oxygen saturation (rSO 2 ). Results We found no significant differences between the patient groups except for a significant increase in mean arterial blood pressure and an increase in rSO 2 after testing. One patient with cerebral vasculopathy had a significant increase in his NSE values without showing clinical symptoms. This patient also had low rSO 2 measurements and a decrease in medial cerebral artery velocity after DFT, other than the other patients. Conclusion Single DFT did not lead to signs of neuronal damage or cognitive impairment except in one case with pre‐existing cerebral vasculopathy. Therefore, our results support the use of DFT in carefully selected patients.
No takes yet. Share an insight, caveat, or question.
Gestrich et al. (2021) conducted an observational in Transvenous ICD implantation (n=23). Single defibrillator testing (DFT) vs. No defibrillator testing was evaluated on Clinical outcomes, neuronal damage parameters (NSE and S100), and intraoperative cerebral perfusion. Single defibrillator testing during ICD implantation showed no significant differences in neuronal damage or cognitive impairment compared to untested patients.
Synapse has enriched 10 related papers. Consider them for comparative context: